Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Novartis
Novartis
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC